143 related articles for article (PubMed ID: 12523881)
21. Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial.
Mansouri K; Orguel S; Mermoud A; Haefliger I; Flammer J; Ravinet E; Shaarawy T
Br J Ophthalmol; 2008 Mar; 92(3):332-6. PubMed ID: 18211927
[TBL] [Abstract][Full Text] [Related]
22. Eyelid hypertrichosis associated with latanoprost is reversible.
O'Toole L; Cahill M; O'Brien C
Eur J Ophthalmol; 2001; 11(4):377-9. PubMed ID: 11820311
[TBL] [Abstract][Full Text] [Related]
23. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
Chou SY; Chou CK; Kuang TM; Hsu WM
Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
[TBL] [Abstract][Full Text] [Related]
24. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys.
Prota G; Vincensi MR; Napolitano A; Selen G; Stjernschantz J
Pigment Cell Res; 2000 Jun; 13(3):147-50. PubMed ID: 10885672
[TBL] [Abstract][Full Text] [Related]
25. Late postoperative choroidal detachment following an uneventful cataract surgery in a patient on topical latanoprost.
Krishnamurthy R; Senthil S; Garudadri CS
BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26174734
[TBL] [Abstract][Full Text] [Related]
26. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
Imesch PD; Wallow IH; Albert DM
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
[TBL] [Abstract][Full Text] [Related]
27. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma.
Nagar M; Ogunyomade A; O'Brart DP; Howes F; Marshall J
Br J Ophthalmol; 2005 Nov; 89(11):1413-7. PubMed ID: 16234442
[TBL] [Abstract][Full Text] [Related]
28. Effect of previous argon laser trabeculoplasty on the ocular hypotensive action of latanoprost.
Arranz-Marquez E; Teus MA
Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1073-6. PubMed ID: 16416130
[TBL] [Abstract][Full Text] [Related]
29. Effect of age on the development of a latanoprost-induced increase in iris pigmentation.
Arranz-Marquez E; Teus MA
Ophthalmology; 2007 Jul; 114(7):1255-8. PubMed ID: 17306877
[TBL] [Abstract][Full Text] [Related]
30. Latanoprost and pigmentation.
Grierson I; Jonsson M; Cracknell K
Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
[TBL] [Abstract][Full Text] [Related]
31. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
Sponsel WE; Paris G; Trigo Y; Pena M
Am J Ophthalmol; 2002 Oct; 134(4):552-9. PubMed ID: 12383812
[TBL] [Abstract][Full Text] [Related]
32. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
Grierson I; Lee WR; Albert DM
Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
[No Abstract] [Full Text] [Related]
33. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
34. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
[TBL] [Abstract][Full Text] [Related]
35. Iris cyst secondary to latanoprost mimicking iris melanoma.
Browning DJ; Perkins SL; Lark KK
Am J Ophthalmol; 2003 Mar; 135(3):419-21. PubMed ID: 12614778
[TBL] [Abstract][Full Text] [Related]
36. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
Wistrand PJ; Stjernschantz J; Olsson K
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
[TBL] [Abstract][Full Text] [Related]
37. Latanoprost-induced iris color darkening: a case report with long-term follow-up.
Camras CB; Neely DG; Weiss EL
J Glaucoma; 2000 Feb; 9(1):95-8. PubMed ID: 10708238
[TBL] [Abstract][Full Text] [Related]
38. Monte Carlo simulation of latanoprost induced iris darkening.
Cracknell KP; Farnell DJ; Grierson I
Comput Methods Programs Biomed; 2007 Aug; 87(2):93-103. PubMed ID: 17576020
[TBL] [Abstract][Full Text] [Related]
39. Production of prostaglandin e(2) by iridial melanocytes exposed to latanoprost acid, a prostaglandin F(2 alpha) analogue.
Bergh K; Wentzel P; Stjernschantz J
J Ocul Pharmacol Ther; 2002 Oct; 18(5):391-400. PubMed ID: 12419090
[TBL] [Abstract][Full Text] [Related]
40. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
Alm A; Grunden JW; Kwok KK
J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
